Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,294,540

« Back to Dashboard
Patent 6,294,540 protects TRIZIVIR, TRIUMEQ, EPZICOM, and ZIAGEN, and is included in five NDAs. There have been zero Paragraph IV challenges on Ziagen, Trizivir, and . There are fifteen tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for TRIZIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-eight patent family members in forty-seven countries.

Summary for Patent: 6,294,540

Title: Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Abstract:The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Inventor(s): Brodie; Alastair Couper (London, GB), Jones; Martin Francis (Kneloworth, GB), Seager; John Frederick (Ware, GB), Wallis; Christopher John (Rayston, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/423,982
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation; Dosage form; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 3rd percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Viiv Hlthcare
abacavir sulfate; lamivudine; zidovudine
TABLET;ORAL021205-001Nov 14, 2000RXYes6,294,540*PEDNov 14, 2018Y
Viiv Hlthcare
abacavir sulfate; dolutegravir sodium; lamivudine
TABLET;ORAL205551-001Aug 22, 2014RXYes6,294,540*PEDNov 14, 2018Y
Viiv Hlthcare
abacavir sulfate; lamivudine
TABLET;ORAL021652-001Aug 2, 2004RXYes6,294,540*PEDNov 14, 2018Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,294,540

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9709945May 17, 1997
PCT Information
PCT FiledMay 14, 1998PCT Application Number:PCT/EP98/02835
PCT Publication Date:November 26, 1998PCT Publication Number: WO98/52949

International Patent Family for Patent: 6,294,540

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.